Stay updated with breaking news from Statistically Significant. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-Phase 3 Study Achieves Primary Endpoint for Both Dosage Strengths of Brensocatib with Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus
Biopharma stock Insmed (Nasdaq: INSM) doubles on Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis
Statistically Significant and Clinically Meaningful Increasein Primary Efficacy Endpoint at 24 Weeks of Treatment; Improvement Consistent Across All Prespecified Subgroups Statistically Significant...
Statistically Significant and Clinically Meaningful Increase in Primary Efficacy Endpoint at 24 Weeks of Treatment; Improvement Consistent Across All…
Media contact: Investor contact: ...